The latest price target for bluebird bio (NASDAQ:BLUE) was reported by RBC Capital on November 15, 2024. The analyst firm set a price target for $4.00 expecting BLUE to fall to within 12 months (a possible -48.05% downside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for bluebird bio (NASDAQ:BLUE) was provided by RBC Capital, and bluebird bio reiterated their sector perform rating.

The last upgrade for bluebird bio Inc happened on December 8, 2023 when Morgan Stanley raised their price target to $7. Morgan Stanley previously had an underweight for bluebird bio Inc.

The last downgrade for bluebird bio Inc happened on November 15, 2024 when B of A Securities changed their price target from $3 to $0.5 for bluebird bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bluebird bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bluebird bio was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest bluebird bio (BLUE) rating was a reiterated with a price target of $4.00 to $4.00. The current price bluebird bio (BLUE) is trading at is $7.70, which is out of the analyst’s predicted range.